Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.

Smith EL, Mailankody S, Staehr M, Wang X, Senechal B, Purdon TJ, Daniyan AF, Geyer MB, Goldberg AD, Mead E, Santomasso BD, Landa J, Rimner A, Riviere I, Landgren O, Brentjens RJ.

Cancer Immunol Res. 2019 Jul;7(7):1047-1053. doi: 10.1158/2326-6066.CIR-18-0551. Epub 2019 May 21.

PMID:
31113804
2.

Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.

Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Palomba ML, Halton E, Bernal Y, van Leeuwen DG, Sadelain M, Park JH, Brentjens RJ.

JCI Insight. 2019 Apr 2;5. pii: 122627. doi: 10.1172/jci.insight.122627.

4.

BRAF in the cross-hairs.

Geyer MB, Abdel-Wahab O, Tallman MS.

Expert Rev Hematol. 2019 Mar;12(3):183-193. doi: 10.1080/17474086.2019.1583553. Epub 2019 Feb 26.

PMID:
30782032
5.

Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia.

Xiao W, Goldberg AD, Famulare CA, Devlin SM, Nguyen NT, Sim S, Kabel CC, Patel MA, McGovern EM, Patel A, Schulman J, Dunbar AJ, Epstein-Peterson ZD, Menghrajani KN, Getta BM, Cai SF, Geyer MB, Glass JL, Taylor J, Viny AD, Levine RL, Zhang Y, Giralt SA, Klimek V, Tallman MS, Roshal M.

Haematologica. 2019 Jul;104(7):1378-1387. doi: 10.3324/haematol.2018.203018. Epub 2018 Dec 6.

6.

First CAR to Pass the Road Test: Tisagenlecleucel's Drive to FDA Approval.

Geyer MB.

Clin Cancer Res. 2019 Feb 15;25(4):1133-1135. doi: 10.1158/1078-0432.CCR-18-3328. Epub 2018 Nov 21.

PMID:
30463849
7.

Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.

Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Halton E, Lamanna N, Rademaker J, Sadelain M, Brentjens RJ, Park JH.

Mol Ther. 2018 Aug 1;26(8):1896-1905. doi: 10.1016/j.ymthe.2018.05.018. Epub 2018 Jun 15.

8.

The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia.

Hochberg J, Zahler S, Geyer MB, Chen N, Krajewski J, Harrison L, Militano O, Ozkaynak MF, Cheerva AC, Talano J, Moore TB, Gillio AP, Walters MC, Baxter-Lowe LA, Hamby C, Cairo MS.

Bone Marrow Transplant. 2019 Feb;54(2):226-235. doi: 10.1038/s41409-018-0247-9. Epub 2018 Jun 13.

PMID:
29899571
9.

Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.

Geyer MB, Manjunath SH, Evans AG, Park JH, Davila ML, Cutler CS, Wang X, Wang Y, Senechal B, Rivière I, Sadelain M, Liesveld JL, Brentjens RJ.

Leuk Lymphoma. 2018 Jul;59(7):1717-1721. doi: 10.1080/10428194.2017.1390237. Epub 2017 Oct 18. No abstract available.

10.

Digging deeper in relapsed acute lymphoblastic leukemia: impact of MRD status on outcome in second remission.

Geyer MB, Tallman MS.

Leuk Lymphoma. 2018 Feb;59(2):269-271. doi: 10.1080/10428194.2017.1355971. Epub 2017 Jul 28. No abstract available.

PMID:
28750565
11.

Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis.

Geyer MB, Hsu M, Devlin SM, Tallman MS, Douer D, Park JH.

Blood. 2017 Mar 30;129(13):1878-1881. doi: 10.1182/blood-2016-11-749507. Epub 2017 Jan 25. No abstract available.

12.

Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.

Geyer MB, Brentjens RJ.

Cytotherapy. 2016 Nov;18(11):1393-1409. doi: 10.1016/j.jcyt.2016.07.003. Epub 2016 Aug 31. Review.

13.

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.

Park JH, Geyer MB, Brentjens RJ.

Blood. 2016 Jun 30;127(26):3312-20. doi: 10.1182/blood-2016-02-629063. Epub 2016 May 20. Review.

14.

Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa.

Geyer MB, Radhakrishnan K, Giller R, Umegaki N, Harel S, Kiuru M, Morel KD, LeBoeuf N, Kandel J, Bruckner A, Fabricatore S, Chen M, Woodley D, McGrath J, Baxter-Lowe L, Uitto J, Christiano AM, Cairo MS.

J Pediatr. 2015 Sep;167(3):765-9.e1. doi: 10.1016/j.jpeds.2015.05.051. Epub 2015 Jul 3.

PMID:
26148662
15.

Enhanced survival during experimental Listeria monocytogenes sepsis in neonatal mice prophylactically treated with Th1 and macrophage immunoregulatory cytokines and mediators.

Geyer MB, Radhakrishnan K, Van de Ven C, Suri MS, Ayello J, Cairo MS.

Pediatr Infect Dis J. 2014 Dec;33(12):e330-7. doi: 10.1097/INF.0000000000000442.

PMID:
24911893
16.

Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.

Bhatia M, Jin Z, Baker C, Geyer MB, Radhakrishnan K, Morris E, Satwani P, George D, Garvin J, Del Toro G, Zuckerman W, Lee MT, Licursi M, Hawks R, Smilow E, Baxter-Lowe LA, Schwartz J, Cairo MS.

Bone Marrow Transplant. 2014 Jul;49(7):913-20. doi: 10.1038/bmt.2014.84. Epub 2014 May 5.

PMID:
24797180
17.

A comparison of bronchoalveolar lavage versus lung biopsy in pediatric recipients after stem cell transplantation.

Qualter E, Satwani P, Ricci A, Jin Z, Geyer MB, Alobeid B, Radhakrishnan K, Bye M, Middlesworth W, Della-Letta P, Behr G, Muniz M, van de Ven C, Harrison L, Morris E, Cairo MS.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1229-37. doi: 10.1016/j.bbmt.2014.04.019. Epub 2014 Apr 23.

18.

Pilot trial of risk-adapted cyclophosphamide intensity based conditioning and HLA matched sibling and unrelated cord blood stem cell transplantation in newly diagnosed pediatric and adolescent recipients with acquired severe aplastic anemia.

McGuinn C, Geyer MB, Jin Z, Garvin JH, Satwani P, Bradley MB, Bhatia M, George D, Duffy D, Morris E, van de Ven C, Schwartz J, Baxter-Lowe LA, Cairo MS.

Pediatr Blood Cancer. 2014 Jul;61(7):1289-94. doi: 10.1002/pbc.24976. Epub 2014 Feb 12.

PMID:
24623601
19.

Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report.

Barth MJ, Goldman S, Smith L, Perkins S, Shiramizu B, Gross TG, Harrison L, Sanger W, Geyer MB, Giulino-Roth L, Cairo MS.

Br J Haematol. 2013 Sep;162(5):678-83. doi: 10.1111/bjh.12434. Epub 2013 Jun 27.

20.

Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease.

Radhakrishnan K, Bhatia M, Geyer MB, Del Toro G, Jin Z, Baker C, Harrison L, Morris E, Baxter-Lowe LA, Cairo MS.

Biol Blood Marrow Transplant. 2013 Apr;19(4):676-7. doi: 10.1016/j.bbmt.2013.02.002. Epub 2013 Feb 9. No abstract available.

21.

Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.

Goldman S, Smith L, Anderson JR, Perkins S, Harrison L, Geyer MB, Gross TG, Weinstein H, Bergeron S, Shiramizu B, Sanger W, Barth M, Zhi J, Cairo MS.

Leukemia. 2013 Apr;27(5):1174-7. doi: 10.1038/leu.2012.255. Epub 2012 Sep 3. No abstract available.

22.

The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients.

Le Gall JB, Milone MC, Waxman IM, Shaw LM, Harrison L, Duffy D, van de Ven C, Militano O, Geyer MB, Morris E, Bhatia M, Satwani P, George D, Garvin JH, Bradley MB, Schwartz J, Baxter-Lowe LA, Cairo MS.

Bone Marrow Transplant. 2013 Jan;48(1):19-25. doi: 10.1038/bmt.2012.105. Epub 2012 Jun 11.

PMID:
22684047
23.

T cell depletion utilizing CD34(+) stem cell selection and CD3(+) addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients.

Geyer MB, Ricci AM, Jacobson JS, Majzner R, Duffy D, Van de Ven C, Ayello J, Bhatia M, Garvin JH Jr, George D, Satwani P, Harrison L, Morris E, Semidei-Pomales M, Schwartz J, Alobeid B, Baxter-Lowe LA, Cairo MS.

Br J Haematol. 2012 Apr;157(2):205-19. doi: 10.1111/j.1365-2141.2012.09048.x. Epub 2012 Feb 8.

PMID:
22313507
24.

A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.

Geyer MB, Jacobson JS, Freedman J, George D, Moore V, van de Ven C, Satwani P, Bhatia M, Garvin JH, Bradley MB, Harrison L, Morris E, Della-Latta P, Schwartz J, Baxter-Lowe LA, Cairo MS.

Br J Haematol. 2011 Oct;155(2):218-34. doi: 10.1111/j.1365-2141.2011.08822.x. Epub 2011 Aug 16.

25.

Cord blood transplantation and stem cell regenerative potential.

Liao Y, Geyer MB, Yang AJ, Cairo MS.

Exp Hematol. 2011 Apr;39(4):393-412. doi: 10.1016/j.exphem.2011.01.002. Epub 2011 Jan 13. Review.

PMID:
21238533

Supplemental Content

Loading ...
Support Center